Click here to get full coverage on Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm

Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission  Sahm

Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm

Click here to get full coverage on Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - simplywall.st

Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy  simplywall.st

Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - simplywall.st

Click here to get full coverage on JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Yahoo Finance

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update  Yahoo Finance

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Yahoo Finance

Click here to get full coverage on COGT: Bezuclastinib advances toward U.S. launch after positive pivotal trials and robust financial positioning - TradingView — Track All Markets

COGT: Bezuclastinib advances toward U.S. launch after positive pivotal trials and robust financial positioning  TradingView — Track All Markets

COGT: Bezuclastinib advances toward U.S. launch after positive pivotal trials and robust financial positioning - TradingView — Track All Markets

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1% - Still a Buy? - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1% - Still a Buy?  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1% - Still a Buy? - MarketBeat

Click here to get full coverage on H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52 - 富途牛牛

H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52  富途牛牛

H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52 - 富途牛牛

Click here to get full coverage on (COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(COGT) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Cogent Biosciences: Time For A Pause (NASDAQ:COGT) - Seeking Alpha

Cogent Biosciences: Time For A Pause (NASDAQ:COGT)  Seeking Alpha

Cogent Biosciences: Time For A Pause (NASDAQ:COGT) - Seeking Alpha

Click here to get full coverage on Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan

Cancer drug maker lays out 2026 plans for new treatments and trials  Stock Titan

Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan

Click here to get full coverage on New Analyst Forecast: $COGT Given $52 Price Target - Quiver Quantitative

New Analyst Forecast: $COGT Given $52 Price Target  Quiver Quantitative

New Analyst Forecast: $COGT Given $52 Price Target - Quiver Quantitative

Click here to get full coverage on H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Yahoo Finance

H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT)  Yahoo Finance

H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Yahoo Finance

Click here to get full coverage on Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛

Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55  富途牛牛

Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛

Click here to get full coverage on A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance

A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing  Yahoo Finance

A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance

Click here to get full coverage on Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment? - simplywall.st

Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment?  simplywall.st

Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment? - simplywall.st

Click here to get full coverage on Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? - Yahoo Finance

Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed?  Yahoo Finance

Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - simplywall.st

Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission  simplywall.st

Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - simplywall.st

Click here to get full coverage on Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Yahoo Finance

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So  Yahoo Finance

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Yahoo Finance

Click here to get full coverage on Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance

Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans  Yahoo Finance

Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance

Click here to get full coverage on Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Yahoo Finance

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress  Yahoo Finance

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Yahoo Finance

Click here to get full coverage on COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Zacks Investment Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know  Zacks Investment Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Zacks Investment Research

Click here to get full coverage on Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Yahoo Finance

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial  Yahoo Finance

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Yahoo Finance

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat

Click here to get full coverage on COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More  Quiver Quantitative

COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Click here to get full coverage on Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering - Stock Titan

Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering  Stock Titan

Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering - Stock Titan

Click here to get full coverage on New drug for systemic mastocytosis moves into FDA review - Stock Titan

New drug for systemic mastocytosis moves into FDA review  Stock Titan

New drug for systemic mastocytosis moves into FDA review - Stock Titan

Click here to get full coverage on COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success  Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

Click here to get full coverage on Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat

Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT  MarketBeat

Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily

Liquidity Mapping Around (COGT) Price Events  Stock Traders Daily

Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily

Click here to get full coverage on COGT Boom: Is It Time to Cash In? - StocksToTrade

COGT Boom: Is It Time to Cash In?  StocksToTrade

COGT Boom: Is It Time to Cash In? - StocksToTrade

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat

Click here to get full coverage on Insider Selling: Cogent Biosciences (NASDAQ:COGT) Insider Sells 65,000 Shares of Stock - MarketBeat

Insider Selling: Cogent Biosciences (NASDAQ:COGT) Insider Sells 65,000 Shares of Stock  MarketBeat

Insider Selling: Cogent Biosciences (NASDAQ:COGT) Insider Sells 65,000 Shares of Stock - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next  TechStock²

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²

Click here to get full coverage on Cogent Bio surges after late-stage trial data for lead drug - Seeking Alpha

Cogent Bio surges after late-stage trial data for lead drug  Seeking Alpha

Cogent Bio surges after late-stage trial data for lead drug - Seeking Alpha

Click here to get full coverage on Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - Yahoo Finance

Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating  Yahoo Finance

Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - Yahoo Finance

Click here to get full coverage on Why Is Cogent Biosciences Stock (COGT) Up 115% Today? - TipRanks

Why Is Cogent Biosciences Stock (COGT) Up 115% Today?  TipRanks

Why Is Cogent Biosciences Stock (COGT) Up 115% Today? - TipRanks

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat

Click here to get full coverage on Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis

Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News  Trefis

Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis

Click here to get full coverage on Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages  MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews

Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential  DirectorsTalk Interviews

Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat

Click here to get full coverage on Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha

Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT)  Seeking Alpha

Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha

Click here to get full coverage on Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq

Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation  Nasdaq

Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq

Click here to get full coverage on Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st

Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding  simplywall.st

Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st

Click here to get full coverage on Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference  Investing News Network

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network

Click here to get full coverage on Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference  Quiver Quantitative

Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Click here to get full coverage on Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results  StocksToTrade

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade

Click here to get full coverage on Cogent Biosciences: Moving Forward (NASDAQ:COGT) - Seeking Alpha

Cogent Biosciences: Moving Forward (NASDAQ:COGT)  Seeking Alpha

Cogent Biosciences: Moving Forward (NASDAQ:COGT) - Seeking Alpha

Click here to get full coverage on Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - Nasdaq

Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation  Nasdaq

Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - Nasdaq

Click here to get full coverage on Cogent Biosciences, Inc. (COGT) Stock Analysis: Uncovering a 47% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Cogent Biosciences, Inc. (COGT) Stock Analysis: Uncovering a 47% Potential Upside in the Biotech Sector  DirectorsTalk Interviews

Cogent Biosciences, Inc. (COGT) Stock Analysis: Uncovering a 47% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference - Stock Titan

Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference  Stock Titan

Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference - Stock Titan

Click here to get full coverage on Risks Report: Does COGT have consistent dividend growth - July 2025 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn

Risks Report: Does COGT have consistent dividend growth - July 2025 Chart Watch & High Accuracy Trade Signal Alerts  baoquankhu1.vn

Risks Report: Does COGT have consistent dividend growth - July 2025 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn

Click here to get full coverage on Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq

Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation  Nasdaq

Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq

Click here to get full coverage on Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Yahoo Finance

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock  Yahoo Finance

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Yahoo Finance

Click here to get full coverage on Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT) - Seeking Alpha

Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT)  Seeking Alpha

Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT) - Seeking Alpha

Click here to get full coverage on HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation - Nasdaq

HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation  Nasdaq

HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation - Nasdaq

Click here to get full coverage on Why Is Cogent Biosciences Stock Trading Higher Today? - Cogent Biosciences (NASDAQ:COGT) - Benzinga

Why Is Cogent Biosciences Stock Trading Higher Today? - Cogent Biosciences (NASDAQ:COGT)  Benzinga

Why Is Cogent Biosciences Stock Trading Higher Today? - Cogent Biosciences (NASDAQ:COGT) - Benzinga

Click here to get full coverage on MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26 - Nasdaq

MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26  Nasdaq

MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26 - Nasdaq

Click here to get full coverage on Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus

Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis  GuruFocus

Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus

Click here to get full coverage on Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus

Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham |  GuruFocus

Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus

Click here to get full coverage on New Analyst Forecast: $COGT Given $50.0 Price Target - Quiver Quantitative

New Analyst Forecast: $COGT Given $50.0 Price Target  Quiver Quantitative

New Analyst Forecast: $COGT Given $50.0 Price Target - Quiver Quantitative

Click here to get full coverage on Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more - Seeking Alpha

Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more  Seeking Alpha

Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more - Seeking Alpha

Click here to get full coverage on Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Senior Notes Totaling Approximately $475 Million - Quiver Quantitative

Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Senior Notes Totaling Approximately $475 Million  Quiver Quantitative

Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Senior Notes Totaling Approximately $475 Million - Quiver Quantitative

Click here to get full coverage on Cogent Biosciences (COGT) Stock Soars with 135% Increase - GuruFocus

Cogent Biosciences (COGT) Stock Soars with 135% Increase  GuruFocus

Cogent Biosciences (COGT) Stock Soars with 135% Increase - GuruFocus

Click here to get full coverage on New Analyst Forecast: $COGT Given $16.0 Price Target - Quiver Quantitative

New Analyst Forecast: $COGT Given $16.0 Price Target  Quiver Quantitative

New Analyst Forecast: $COGT Given $16.0 Price Target - Quiver Quantitative

Click here to get full coverage on A second win for Cogent pushes the company toward two NDAs - BioWorld MedTech

A second win for Cogent pushes the company toward two NDAs  BioWorld MedTech

A second win for Cogent pushes the company toward two NDAs - BioWorld MedTech

Click here to get full coverage on HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation  Nasdaq

COGT

Price Chart

Key Statistics

Technicals

About COGT

Latest News

Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm

Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - simplywall.st

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers